# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Dyskinesia, Drug Induced

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-5 of 5 results.
Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components
Status: Not yet recruiting
Last Changed: May 14, 2020
First Received: May 07, 2020
Disease(s): Dyskinesia, Drug-Induced
Intervention(s): Part 1, JM-010 component Group A, Part 1, JM-010 component Group B, Part 1, JM-010 component Group C, Part 1, Placebo Group, Part 2, JM-010 combination Group A, Part 2, JM-010 combination Group B, Part 2, Placebo Group, Part 2, JM-010 component Group C
Locations: Bukwang Investigator site, West Bloomfield, Michigan, United States
Safinamide for Levodopa-induced Dyskinesia (PD-LID)
Status: Not yet recruiting
Last Changed: Jun 17, 2019
First Received: Jun 17, 2019
Disease(s): Dyskinesia, Drug-Induced, Parkinson Disease
Intervention(s): Safinamide Methanesulfonate 150mg, Safinamide Methanesulfonate 100mg, Safinamide Methanesulfonate matching placebo
AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia
Status: Not yet recruiting
Last Changed: Jan 14, 2020
First Received: Nov 01, 2019
Disease(s): Parkinson Disease, Dyskinesia, Medication-Induced, L-Dopa Causing Adverse Effects in Therapeutic Use
Intervention(s): AV-101, Placebo
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
Status: Recruiting
Last Changed: Mar 22, 2019
First Received: Apr 11, 2018
Disease(s): Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia, Parkinsonism
Intervention(s): Varenicline
Locations: Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
Status: Recruiting
Last Changed: Sep 11, 2019
First Received: Mar 27, 2019
Disease(s): Tardive Dyskinesia (TD)
Intervention(s): Valbenazine, Placebo oral capsule
Locations: Neurocrine Clinical Site, Little Rock, Arkansas, United States
Neurocrine Clinical Site, Anaheim, California, United States
Neurocrine Clinical Site, Anaheim, California, United States
Neurocrine Clinical Site, Costa Mesa, California, United States
Neurocrine Clinical Site, Escondido, California, United States
... and 39 other locations.